Our Pipeline of Investigational Therapies
Surface Oncology® is developing multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable a robust immunologic response and enhance outcomes for patients with cancer.
Surface’s pipeline spans compelling areas of discovery and development across four key areas of immune modulators to: activate both macrophages and natural killer cells, inhibit or deplete regulatory T cells and block suppressive cell signaling molecules, including cytokines and metabolites.
Wholly Owned Programs
* Surface has paused the clinical development of SRF617.
Licensed Programs
Posters & Publications
The Surface team is committed to scientific exchange and continual learning, from each other, from our work and from experts around the world, to break through scientific challenges.
